• Nexus Pharmaceuticals announces approval of Emerphed injection pharmaceutical-business-review
    April 26, 2020
    Nexus Pharmaceuticals announced that has received U.S. Food and Drug Administration (FDA) approval for its patent-pending New Drug Application (NDA) Emerphed, the first and only premixed ephedrine in a ready-to-use 50 mg/10 mL vial.
PharmaSources Customer Service